Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Formoterol fumarate
Formoterol · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| formoterol | DEVICE | - |
Inclusion Criteria: * Patients who are capable of understanding the directions for device usage, evaluating device function and completing the patient diary * Patients who have a current diagnosis of asthma * Patients who have a documented forced expiratory volume at 1 second (FEV1) reversibility o...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Formoterol is a small molecule drug developed for the treatment of asthma. It is delivered by inhalation and is studied in patients with asthma, including adults and children. The clinical program includes a Phase 3 study in patients aged 5 years and older and a Phase 2 study in adults.
Formoterol targets ADRB2, the beta-2 adrenergic receptor, and acts as an agonist at this receptor. This target class places formoterol among the beta-2 adrenergic receptor agonists used in respiratory medicine. Its activity at ADRB2 is the basis for its development in asthma.
Formoterol is developed by Novartis AG, which trades under the ticker NVS. Novartis is the company associated with the clinical development program for formoterol in asthma, including the Phase 3 and Phase 2 studies listed for the drug.
Formoterol is in Phase 3 development for asthma. It is an investigational small molecule and is not described as approved. The program includes two completed trials, one Phase 3 and one Phase 2, with no active trials currently listed.
Formoterol has been studied in two completed trials. NCT00130351 was a 3-week Phase 3 study of patient use and functionality of formoterol in a novel inhalation device in asthma patients aged 5 years and older in the United States. NCT00443482 was a Phase 2 equivalence study of formoterol 12 and 24 µg delivered via two single dose dry powder inhalers in Germany.
Yes, formoterol is also known as formoterol fumarate, and it has been referred to as formoterol (12 µg b.i.d.). These names refer to the same drug, a small molecule developed by Novartis AG for asthma. Searches using any of these names point to the same asset.